{"id":680874,"date":"2023-12-12T18:14:02","date_gmt":"2023-12-12T18:14:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=680874"},"modified":"2023-12-12T18:14:02","modified_gmt":"2023-12-12T18:14:02","slug":"antimicrobial-resistance-surveillance-market-worth-77-billion-marketsandmarkets","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/antimicrobial-resistance-surveillance-market-worth-77-billion-marketsandmarkets_680874.html","title":{"rendered":"Antimicrobial Resistance Surveillance Market worth $7.7 billion | MarketsandMarkets"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\">\n<div><a href=\"https:\/\/www.abnewswire.com\/uploads\/1702368717.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Antimicrobial Resistance Surveillance Market worth $7.7 billion | MarketsandMarkets\" src=\"https:\/\/www.abnewswire.com\/uploads\/1702368717.jpeg\" alt=\"Antimicrobial Resistance Surveillance Market worth $7.7 billion | MarketsandMarkets\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/div>\n<div class=\"quotes\">\n<div>North America accounted for the largest share the antimicrobial resistance surveillance market. During forecast period, Asia Pacific to witness high growth rate. America.<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">The global antimicrobial resistance surveillance market in terms of revenue was estimated to be worth $5.9 billion in 2023 and is poised to reach $7.7 billion by 2028, growing at a CAGR of 5.6% from 2023 to 2028. The new research study consists of an industry trend analysis of the market.<\/div>\n<p style=\"text-align: justify;\"><strong><a href=\"https:\/\/www.marketsandmarkets.com\/Market-Reports\/antimicrobial-resistance-surveillance-market-21323165.html?utm_source=ABnewswire&amp;utm_campaign=Paid&amp;utm_content=Referral\" target=\"_blank\">Antimicrobial Resistance Surveillance Market<\/a><\/strong>&nbsp;in terms of revenue was estimated to be worth&nbsp;$5.9 billion&nbsp;in 2023 and is poised to reach&nbsp;$7.7 billion&nbsp;by 2028, growing at a CAGR of 5.6% from 2023 to 2028 according to a new report by MarketsandMarkets&trade;. Growth in this market is majorly driven by growing prevalence of infections caused by drug-resistance pathogens, innovations in diagnostic technologies, and growing government initiatives to combat antimicrobial-resistance species.<\/p>\n<p style=\"text-align: justify;\"><strong>Download an Illustrative overview:&nbsp;<a href=\"https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=21323165&amp;utm_source=ABnewswire&amp;utm_campaign=Paid&amp;utm_content=Referral\" target=\"_blank\">https:\/\/www.marketsandmarkets.com\/pdfdownloadNew.asp?id=21323165<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>The diagnostic kits segment is expected to account for the largest share of the market during the forecast period<\/strong><\/p>\n<p style=\"text-align: justify;\">On the basis of solutions, the global antimicrobial resistance surveillance market has been segmented into diagnostic kits, diagnostic systems, surveillance software, and services. In 2023, the diagnostic kits segment is estimated to command the largest share of the global antimicrobial resistance surveillance market. The large share of this segment can primarily be attributed to the increasing demand for rapid and accurate diagnostics for antimicrobial resistance. Diagnostic kits are used to detect the presence of antimicrobial-resistant bacteria in clinical samples, such as blood, urine, and respiratory secretions.<\/p>\n<p style=\"text-align: justify;\"><strong>The clinical diagnostics segment is expected to account for the largest share of the market during the forecast period.<\/strong><\/p>\n<p style=\"text-align: justify;\">On the basis of application, the global antimicrobial resistance surveillance market has been segmented into clinical diagnostics, public health surveillance, and other applications. In 2023, the clinical diagnostics segment is expected to command the largest share of the global antimicrobial resistance surveillance market. The growth in this segment can be attributed to factors such as need to improve patient outcomes, increasing prevalence of antimicrobial resistance, used to determine the susceptibility of bacteria to different antimicrobial agents.<\/p>\n<p style=\"text-align: justify;\"><strong>The hospitals &amp; clinics segment is expected to account for the largest share of the market<\/strong><\/p>\n<p style=\"text-align: justify;\">On the basis of end users, the global antimicrobial resistance surveillance market has been segmented into hospitals &amp; clinics, research and academic institutes, and others. In 2023, the hospitals &amp; clinics segment is expected to command the largest share of the global antimicrobial resistance surveillance market.The large share of this segment can be attributed to the fact that because they are the primary settings where antimicrobial-resistant infections occur and they are required to conduct antimicrobial resistance surveillance.<\/p>\n<p style=\"text-align: justify;\"><strong>Asia Pacific&nbsp;to witness the highest growth during the forecast period.<\/strong><\/p>\n<p style=\"text-align: justify;\">In 2022,&nbsp;North America&nbsp;accounted for the largest share the antimicrobial resistance surveillance market. During forecast period,&nbsp;Asia Pacific&nbsp;to witness high growth rate. America. The&nbsp;Asia Pacific&nbsp;region is expected to offer significant opportunities for the growth of the antimicrobial susceptibility testing market. This is because of the region&#8217;s large population and its mix of growing and developed economies, such as&nbsp;Japan,&nbsp;China, and&nbsp;India. In addition, markets in developed countries are becoming increasingly saturated. As a result, manufacturers and suppliers are shifting their focus to&nbsp;Asia Pacific.<\/p>\n<p style=\"text-align: justify;\"><strong>Request Sample Pages:&nbsp;<a href=\"https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=21323165&amp;utm_source=ABnewswire&amp;utm_campaign=Paid&amp;utm_content=Referral\" target=\"_blank\">https:\/\/www.marketsandmarkets.com\/requestsampleNew.asp?id=21323165<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Antimicrobial Resistance Surveillance Market&nbsp;Dynamics:<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Drivers:<\/strong>1.&nbsp; Growing prevalence of infections caused by drug-resistance pathogens<\/p>\n<p style=\"text-align: justify;\"><strong>Restraints:<\/strong>1.&nbsp; High cost of antimicrobial resistance diagnostic systems\/ kits<\/p>\n<p style=\"text-align: justify;\"><strong>Opportunities:<\/strong>1.&nbsp; Growth opportunities in emerging economies<\/p>\n<p style=\"text-align: justify;\"><strong>Challenge:<\/strong>1.&nbsp; Complex Regulatory Frameworks<\/p>\n<p style=\"text-align: justify;\"><strong>Key Market Players:<\/strong><\/p>\n<p style=\"text-align: justify;\">The prominent players in this market are Biomerieux (France), Lumed (US), Liofilchem S.r.l. (Italy), BioSpace (US), Bruker (US), Bio-Rad (US), Abbott Laboratories (US), Qiagen (Germany), Cepheid (US), Accelerate Diagnostics, Inc. (US), Roche Diagnostics (Switzerland),&nbsp; Luminex Corporation (US), Merck KgaA (Germany), Thermo Fisher Scientific (US), Danaher (US), Becton, Dickinson and Company (US), OpGen, Inc. (US), Alifax S.r.l. (Italy),&nbsp;Wolters Kluwer N.V.&nbsp;(US), and Bioanalyse (Turkey).<\/p>\n<p style=\"text-align: justify;\"><strong>Get 10% Free Customization on this Report:&nbsp;<a href=\"https:\/\/www.marketsandmarkets.com\/requestCustomizationNew.asp?id=21323165&amp;utm_source=ABnewswire&amp;utm_campaign=Paid&amp;utm_content=Referral\" target=\"_blank\">https:\/\/www.marketsandmarkets.com\/requestCustomizationNew.asp?id=21323165<\/a><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/marketsandmarkets.com_17712.html\" rel=\"nofollow\">MarketsandMarkets\u2122 Research Private Ltd.<\/a><br \/><strong>Contact Person:<\/strong> Mr. Aashish Mehra<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=antimicrobial-resistance-surveillance-market-worth-77-billion-marketsandmarkets\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 18886006441<br \/><strong>Address:<\/strong>630 Dundee Road  Suite 430<br \/><strong>City:<\/strong> Northbrook<br \/><strong>State:<\/strong> IL 60062<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.marketsandmarkets.com\/Market-Reports\/antimicrobial-resistance-surveillance-market-21323165.html\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.marketsandmarkets.com\/Market-Reports\/antimicrobial-resistance-surveillance-market-21323165.html<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.marketsandmarkets.com\/Market-Reports\/antimicrobial-resistance-surveillance-market-21323165.html\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=antimicrobial-resistance-surveillance-market-worth-77-billion-marketsandmarkets\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>North America accounted for the largest share the antimicrobial resistance surveillance market. During forecast period, Asia Pacific to witness high growth rate. America. The global antimicrobial resistance surveillance market in terms of revenue was estimated to be worth $5.9 billion &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/antimicrobial-resistance-surveillance-market-worth-77-billion-marketsandmarkets_680874.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,403,404,416],"tags":[],"class_list":["post-680874","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-UK","category-US","category-World"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/680874","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=680874"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/680874\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=680874"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=680874"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=680874"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}